Opinion|Videos|November 1, 2024
Mechanisms of Acquired Resistance in First-Line Treatment – Amivantamab plus Lazertinib vs. Osimertinib
Author(s)Hatim Husain, MD
Panelist discusses how an early analysis of the mechanisms of acquired resistance to first-line treatment with amivantamab plus lazertinib vs osimertinib was presented at the European Society for Medical Oncology Congress 2024, shedding light on potential strategies for managing EGFR-mutated and MET-amplified non–small cell lung cancer.
Advertisement
Episodes in this series
Video content above is prompted by the following:
An early analysis of the mechanisms of acquired resistance to first-line treatment with amivantamab plus lazertinib vs osimertinib was presented at the European Society for Medical Oncology Congress 2024.
Please discuss the findings and their implications on the frontline treatment decisions for patients with EGFR mutations or MET amplification.
Advertisement
Related to this article
SABR had higher 3-year all-cause mortality than surgery in early-stage NSCLC (30.3% vs 21.6%) in an emulated target trial; the gap narrowed at age 80 and older.
Hoth Therapeutics stopped the phase 2a CLEER-001 trial of topical HT-001 early after an interim review and will seek FDA input on phase 3.
Hear how a single ctDNA blood draw 3 to 9 weeks into immunotherapy may reveal response earlier than imaging in NSCLC, with Valsamo Anagnostou, MD, PhD.
Real-world study shows outpatient tarlatamab for relapsed SCLC is feasible, with mostly low-grade CRS, rare ICANS, low ICU use, and similar disease control.
Catch up on October 2026 FDA oncology actions: approvals for pirtobrutinib, tucatinib, and dostarlimab, plus BLA and NDA submissions and a new designation.
New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
Phase 3 data at ESMO 2026: sac-TMT and iza-bren beat chemotherapy in NSCLC, while chemo plus pembrolizumab extended PFS in PD-L1–high disease.
ESMO 2026 Presidential Symposium II recap: survival benefits reported across phase 3 Krascendo 1, SAFFRON, CLARITY-Gastric01, and HARMONi-GI1 trials.
Advertisement
Advertisement
Trending on Targeted Onc
1
A New Era in Sarcoma Treatment? Dr Banks on the Potential of TIL Therapy
2
FDA Approves Generic Venetoclax Tablets for CLL/SLL and AML
3
Enzalutamide Fails to Improve Survival in High-Risk Prostate Cancer
4
Neoadjuvant Botensilimab/Balstilimab Shows Activity in Colon Cancer
5